Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Crespo

Showing results (301-310 of 365) with videos related to

Pageof 37
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2017
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 InfectionJavier Crespo, Jose Luis Calleja, Inmaculada Fernández, et al.
Revista Espanola De Enfermedades Digestivas|October 29, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Albillos Albillos, María Buti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 16, 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisJörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, et al.
Nature Communications|July 5, 2020
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidationLucía Barbier-Torres, Karen A Fortner, Paula Iruzubieta, et al.
Alimentary Pharmacology & Therapeutics|April 26, 2022
Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter studyLuis Téllez, Eugenia Sánchez Rodríguez, Enrique Rodríguez de Santiago, et al.
Journal of Hepatology|December 31, 2017
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis CJavier Ampuero, Carlota Jimeno, Rosa Quiles, et al.
Hepatology (Baltimore, Md.)|January 10, 2023
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administrationÁlvaro Díaz-González, Manuel Hernández-Guerra, Indhira Pérez-Medrano, et al.
Journal of Hepatology|February 13, 2017
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohortJose Luis Calleja, Javier Crespo, Diego Rincón, et al.
Oncotarget|August 17, 2018
Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTORSusana Llerena, Nuria García-Díaz, Soraya Curiel-Olmo, et al.
Molecular Metabolism|July 15, 2023
Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial functionMaria J Gonzalez-Rellan, Tamara Parracho, Violeta Heras, et al.
Pageof 37

Showing results (301-310 of 365) with videos related to

Sort By:
Pageof 37
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2017
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 InfectionJavier Crespo, Jose Luis Calleja, Inmaculada Fernández, et al.
Revista Espanola De Enfermedades Digestivas|October 29, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Albillos Albillos, María Buti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 16, 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisJörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, et al.
Nature Communications|July 5, 2020
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidationLucía Barbier-Torres, Karen A Fortner, Paula Iruzubieta, et al.
Alimentary Pharmacology & Therapeutics|April 26, 2022
Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter studyLuis Téllez, Eugenia Sánchez Rodríguez, Enrique Rodríguez de Santiago, et al.
Journal of Hepatology|December 31, 2017
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis CJavier Ampuero, Carlota Jimeno, Rosa Quiles, et al.
Hepatology (Baltimore, Md.)|January 10, 2023
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administrationÁlvaro Díaz-González, Manuel Hernández-Guerra, Indhira Pérez-Medrano, et al.
Journal of Hepatology|February 13, 2017
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohortJose Luis Calleja, Javier Crespo, Diego Rincón, et al.
Oncotarget|August 17, 2018
Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTORSusana Llerena, Nuria García-Díaz, Soraya Curiel-Olmo, et al.
Molecular Metabolism|July 15, 2023
Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial functionMaria J Gonzalez-Rellan, Tamara Parracho, Violeta Heras, et al.
Pageof 37